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A recent paper from Moonla et al addressed the huge concern
of coagulation disorders in COVID-19.1 The current debate
about blood clots, following administration of some vaccine
formulas, is harassing the scientific community. Experts in the
field are striving to make people trusted about the negligible
hazard associated with those vaccines. Yet, truth is hidden
within some fundamental evidence, which deserves further
research. A paper from Stone et al, published on 2007, showed
that the delivery of the recombinant adenovirus-based vectors
(serotype 5) used for therapy, caused platelet sequestering, thus
triggering their activation and also aggregation, which were
followed by their entrapment in the liver and finally their cap-
ture by Kupffer cells.2 Adenovirus serotype 5 (Ad5) is widely
used as a recombinant, non replicative vector even for
COVID-19 vaccine formulations3,4 and the ability of Ad5
vectors to sequestering platelets, causing temporary thrombo-
cytopenia, has been widely demonstrated.5,6 Moreover, it
seems that Ad5 binds the platelets CD62 and increases
D-dimer for at least 6 hours following Ad5 introduction.2
Recombinant Ad5 therefore can activate platelets. Despite this
in vitro evidence may suggest some criticism about Ad5-based
therapy and support caution in addressing Ad5 vaccine based
safety, the rate of thrombogenic adverse effects is negligible,
amounting to less than 0.00034%.7,8
Driving a car is much more hazardous, taking a flight is
much more hazardous, therefore why fueling an outcry and
enhancing the amount of reluctant people by sequestering
Ad5-based vaccines? The real question is why this occurs and
which subjects are involved.
In the elderly, that is, subjects aged over 65 yrs, a study from
Msaouel et al reported a significant association of thrombocy-
topenia (HR ¼ 1.45; 95% CI: 1.36-1.56) with a decrease in
overall survival respect to individuals with normal platelets
count.9 To prevent this event, though particularly rare, physi-
cians recommending to associate vaccination with salicylate
therapy should be aware that salicylate may be associated with
autoimmunity,10 whereas, very recently, Bruton tyrosine
kinase (BTK) inhibitors are widely recommended to prevent
immune thrombotic thrombocytopenia caused by vaccine-
related adverse effects.11 Common knowledge about
thrombotic mechanism does not associate thrombosis risk with
thrombocytopenia, yet with thrombocytosis, i.e. a platelets
count higher than the normal range is alarming for blood clots,
never the contrary. Yet, it seems that this consideration might
be even flawed.
Blood clots appeared to occur much more frequently in
relatively young women (45-50 yrs) undergoing Ad5-based
vaccination,8 in female subjects thrombocytopenia and micro-
thrombotic events are often associated with hormonal estro-
genic therapy,12 therefore, some news about how come adverse
effects in the coagulation pathway may occur with Ad5 vac-
cines, should find any possible, though anecdotal, explanation.
Briefly speaking, as negligible and very rare are events asso-
ciated with anaphylactic responses toward polyethylenglycole
(PEG), in some vaccine formulation, the same can be argued
about thrombotic very rare occurrences. After reading the very
recent literature, it seems that thrombocytopenia may be one
the leading causes of blood clots causing the rate of mortality
observed upon some vaccination formulas.
For example, immune thrombocytopenia (ITP), contrarily to
the majority of opinions, may cause sporadic cases of throm-
bosis.13 Some authors reported that at least 20 events on 36 ITP
patients resulted in micro-thrombotic events (55.6%), aside
from age distribution and sex, and with a platelet count 100
 103/ml.13 The hypothesis is that platelet microparticles
PMPs), which are particularly frequent in ITP and very hard
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to be detected by routine blood count, may cause thrombotic
events in these subjects.12 PMPs, which can be yet detected by
flow cytometry,14 are generated also in heparin-induced throm-
bocytopenia,15 therefore a thrombocytopenic condition may be
causative of thrombotic events, though anecdotal and
paradoxical.
ITP is very rare, with about 200,000 people worldwide,
increases with increasing ages (over 60) and involves 2.6 times
female subjects than males. Obviously, if this is one of the
possible concern related to Ad5-employing vaccines, an ana-
mnestic and pre-diagnostic panel should be debated within the
scientific and medical community. The conclusion one could
forward is that platelets count may be an early warning to
access Ad5-based vaccination with the highest safety and ana-
mnesis of heparin used as therapy considered a critical issue.
Pragmatism, urgency in vaccinating people during this
COVID-19 emergency and burdensome managing may prevail.
Anyway, this debate should be expanded within experts in the
field and further investigation is needed to improve vaccine
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